source
- Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's preventionLONDON — Eli Lilly, the world’s biggest drugmaker, appears to be getting more ambitious about tackling brain diseases. Last week, the company announced it would pay $2.8 billion upfront to acquire…Endpoints · 10d ago↗ source
- Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease studyA new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…BioPharma Dive · 10d ago↗ source
- STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and morePresident Trump plans to impose tariffs on imported generic medicines, his latest threat aimed at bringing pharmaceutical manufacturing back to the U.S.